TL;DR
The FDA does not pre-review most cosmetic claims before products go to market. Enforcement is reactive: complaints, adverse-event reports, import inspections, and competitor challenges drive action. The FDA’s Office of Cosmetics and Colors handles cosmetic-specific issues; the FTC handles advertising. The 2022 MoCRA law tightened registration and adverse-event reporting but still did not introduce pre-market approval.
The mental model of a federal agency reviewing every moisturizer label before it ships is widespread and almost entirely wrong. The US cosmetic regulatory system is fundamentally post-market: the product goes on the shelf, and intervention only happens after a problem is reported or detected. This is a meaningful difference from the drug or medical device system, where pre-market approval is the default.
What it actually is
The FDA’s Office of Cosmetics and Colors, housed within the Center for Food Safety and Applied Nutrition, has primary jurisdiction over cosmetics. The office is small compared to the drug and medical device offices, and its work is largely surveillance and enforcement rather than approval.
The activities the office actually performs include reviewing voluntary cosmetic ingredient submissions, evaluating adverse-event reports, conducting import sample inspections, issuing warning letters to manufacturers, and coordinating with the FTC on advertising-claim issues. Pre-market label review is not on this list.
The 2022 Modernization of Cosmetics Regulation Act (MoCRA) is the biggest change to US cosmetic regulation in 84 years. It introduced mandatory facility registration, mandatory product listing, mandatory adverse-event reporting, and gave the FDA explicit recall authority for cosmetics. What it did not introduce: pre-market approval. Brands still launch products without FDA sign-off, and the agency’s role is still primarily reactive.
Why it matters
If you assume FDA pre-approval exists, the marketing claim “FDA-compliant” feels meaningful. If you understand pre-approval does not exist for cosmetics, the phrase reduces to “the brand says they followed the rules.” Both descriptions are technically accurate; one is more useful.
The actors who do read your moisturizer label include the brand’s own regulatory team, competing brands looking for FTC violations, consumer advocacy groups, dermatologists filing adverse-event reports, and (post-MoCRA) the FDA when a complaint comes in. The first four are doing most of the policing on a day-to-day basis. The FDA enters when something escalates.
What you can do
For everyday shopping, the “FDA-regulated” label tells you less than you think. The more informative signals are specific ingredient lists, transparent claim substantiation, and adverse-event histories you can find through quick searches.
For products that worry you, the FDA’s MedWatch system accepts adverse-event reports from consumers. Reports that pile up on a specific product or ingredient are what trigger investigations. The system relies on consumer reporting; under-reporting is the standard.
For specific concerns about drug-versus-cosmetic line questions (does this serum claim something that makes it a drug?), the FDA’s labeling guide is the authoritative reference. The categories shift more often than most shoppers expect; ingredients move between cosmetic and OTC drug classification based on the claim being made about them.
The contrarian take: pre-market approval would not solve the things shoppers think it would solve
The instinct to demand FDA pre-approval of cosmetics is understandable, but the model from drug approval would slow the industry to a halt and likely produce no clinical benefit for cosmetic safety. The vast majority of cosmetic adverse events are contact irritation and allergic reactions, both of which are individual to the user and largely unpredictable from formula review.
The more effective interventions are improved adverse-event reporting (which MoCRA addressed), better ingredient labeling (already strong in the US), and consumer education about claim language. Pre-approval would mostly slow product launches without changing the underlying allergy and irritation rates.
Real numbers
The FDA’s 2023 annual report on cosmetic enforcement noted 7,890 adverse-event reports filed through MedWatch and equivalent channels in fiscal year 2023, a sharp increase from prior years driven by the new MoCRA reporting requirements. Of those, the FDA opened formal investigations on approximately 3 percent and issued warning letters on roughly 0.5 percent. Recalls remained rare.
The MoCRA implementation timeline on the FDA’s site lists facility registration requirements taking effect in 2024 and full adverse-event reporting in effect from late 2023. The full enforcement picture for the post-MoCRA era will not stabilize until 2026 or later.
FAQ
Does “FDA-approved” mean anything on a cosmetic? Not really. The FDA does not approve cosmetics. The phrase is sometimes loosely used to mean “the ingredients are on FDA-permitted lists,” which is a much weaker claim.
What about FDA-approved color additives? Color additives ARE pre-approved by the FDA on an ingredient-by-ingredient basis. That is the one area where pre-approval applies. A finished product using approved color additives is still not itself pre-approved.
Who enforces “natural” or “organic” claims? The USDA’s National Organic Program handles certified organic. “Natural” is undefined and largely unpoliced. The FTC may intervene if “natural” is used in a clearly deceptive context.
Can I report a bad reaction to a cosmetic? Yes. MedWatch accepts consumer reports. The reports go into the FDA’s adverse-event database and contribute to surveillance.
What changed with MoCRA? Mandatory facility registration, mandatory adverse-event reporting, mandatory product listing, explicit recall authority, and new fragrance allergen disclosure rules taking effect through 2025 and 2026. The framework is still post-market.
For related context, see the FTC’s role in beauty marketing, where cosmetics end and OTC drugs begin, and what dermatologist-tested legally means.
Tag hub: More on skincare myths and regulation
Sources
US Food and Drug Administration, Cosmetics Q&A and Enforcement Report, fiscal year 2023. Modernization of Cosmetics Regulation Act of 2022, Public Law 117-328. National Institutes of Health, MedWatch Adverse Event Reporting System overview.